StockData
Nuvation Bio Inc. logo

Nuvation Bio Inc. (NUVB) company profile

NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.90+0.06 (+1.56%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

About Nuvation Bio

Pharmaceutical Preparations, SIC 2834

Nuvation Bio Inc. is a biopharmaceutical company that develops and commercializes targeted therapies for cancer patients. The company operates within the oncology sector, discovering and advancing small-molecule treatments and drug-drug conjugates. Its lead commercial medicine is IBTROZI, an oral ROS1 inhibitor approved for adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer. Additionally, the company advances a clinical pipeline that includes safusidenib for patients with IDH1-mutant brain tumors, along with early-stage candidates designed through its drug-drug conjugate platform.

The company operates on an international scale, marketing its lead therapy in the United States and collaborating with regional pharmaceutical partners to commercialize treatments in Japan, China, Europe, and numerous other territories. Its United States commercial footprint includes seventy-one commercial field staff and seven medical affairs representatives. The enterprise owns no manufacturing facilities, relying instead on third-party contract manufacturers for product supply. The provided text does not disclose the location of the company's corporate headquarters.

Summary of the business section of Nuvation Bio's latest annual report, written by StockData.

Company profile

Company

Legal name
Nuvation Bio Inc.
Founded
2018
Headquarters
New York, NY
Address
1500 Broadway, Suite 1401 10036
Phone
(332) 208-6102
Employees
298, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, New York, NY

Stock & identifiers

Ticker
NUVB
Exchange
NYSE
IPO date
Jul 2, 2020
Shares outstanding
351M, Aug 3, 2026
Public float
$496.97M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1811063
CUSIP
67080N101
ISIN
US67080N1019
FIGI
BBG00VHJ0CC1
Share class FIGI
BBG00VHJ0CD0
LEI
2549009IT4XP2SCZTR55
EIN
85-0862255

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David HungPRESIDENT AND CEO, Director59,281,054
Gary HattersleyCHIEF SCIENTIFIC OFFICER0
Philippe SauvageChief Financial Officer54,130
Stacy MarkelCHIEF PEOPLE OFFICER157,591
Kerry WentworthCHIEF REGULATORY OFFICER116,000
Dongfang LiuCHIEF MEDICAL OFFICER68,000
Colleen SjogrenChief Commercial Officer84,000
David C. HanleyCHIEF TECHNICAL OPERATIONS24,000
Moses MakunjeSEE REMARKS68,137
Robert MashalDirector225,000
Xiangmin CuiDirector25,954,439
Robert B. BazemoreDirector5,000
W. Anthony VernonDirector254,100
Kathryn E. FalbergDirector250,000
Kim D. BlickenstaffDirector172,189

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.88M$27.83M$1.48M$77–
FY2024$3.72M$6.54M$1.79M$23–
FY2023$4.32M$2.79M$1.35M$13–
FY2022$8.07M$1.91M$3.64M$16–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
David Hung
President and Chief Executive Officer
$650.02K$2.67M$536.25K$15.83K$3.88M+4%
Philippe Sauvage
Chief Financial Officer
$510.00K$668.66K$252.45K$47.57K$1.48M+24%
Gary Hattersley
Chief Scientific Officer
$515.07K$668.66K$254.93K$35.81K$1.47M+5%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Jul 2, 2020
Offer price
$10.00
Securities offered
12,500,000
Gross proceeds
$125.00M
Exchange
NYSE
First trading day
Aug 21, 2020
First-day close
$10.51+5.0%
Lock-up ends (est.)
Feb 17, 2021

“Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one -third of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 298 full-time employees, 58 of whom hold Ph.Ds, M.Ds or Pharm.Ds.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?